Community Research and Development Information Service - CORDIS

H2020

PNEUMOSIP Report Summary

Project ID: 685052

Periodic Reporting for period 1 - PNEUMOSIP (PNEUMOSIP)

Reporting period: 2015-11-01 to 2016-10-31

Summary of the context and overall objectives of the project

Community acquired pneumonia (CAP), together with lower respiratory tract infections, is the fourth most common cause of death globally, mostly affecting the elderly and children under 5 years of age. Timely diagnosis of the condition, identification of its cause and selection of the treatment is fundamental to reduce loss of lives. However, current diagnostic methods are too slow and increasing antibiotic resistances make it harder to treat. As a result, the societal and economic costs caused by pneumonia cannot be mitigated.
PneumoSIP is a novel solution for the problem of pneumonia, that helps doctors confirm, in less than 2 hours, the existence of the disease, identify what is causing it and provide information to better selector the treatment. Therefore, PneumoSIP provides the right information for doctors to take the best possible decisions: patients are treated faster and better and mortality is reduced. PneumoSIP also improves the efficiency of Europe’s healthcare system by allowing hospitals to do more work in less time and reducing the overall costs due to testing, hospitalization and incorrect treatment.
PneumoSIP’s main objective is to minimize loss of life due to pneumonia by providing a fast, accurate, affordable and fully automated solution. PneumoSIP can be used by a variety of healthcare professionals in most healthcare centres, thus being available for the whole society.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

During the reporting period, the first prototype of the PneumoSIP device has been assembled and it is currently undergoing tests prior to pre-clinical validation at the beginning of 2017. All the components are functional and the core element “qPCR machine” has proven superiority in tests against a well-known commercial device (Applied BioSciences 7500). Two patents have been generated in relation to the device.
The cartridges for the reagents have been fabricated and they are currently undergoing optimizations (dimensional, cleanliness, filling and sealing) as a preparation towards the final phases of the pre-clinical validation and the clinical validation. One patent has been generated in relation to the cartridge.
The protocol for bacterial nucleic acids extraction and their associated antibiotic resistances has been completed. The qPCR reactions are also ready.
Agreements have been signed with all the Hospitals involved in the proposal and a fourth one has been added for the purpose of sample provision, since it is expected that numbers from the other three hospitals may not be enough. Collection has already started in some of these hospitals in preparation for the pre-clinical and clinical validation.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The progress beyond the state-of-the-art is due to PneumoSIP’s three patents. Despite the protection, the applications are recent and AlphaSIP must maintain this information confidential.

Related information

Record Number: 198245 / Last updated on: 2017-05-18
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top